Trial Profile
A Pilot Study of Avatrombopag for Temozolomide-induced Thrombocytopenia in Glioma (APATIT-G)
Status:
Recruiting
Phase of Trial:
Phase 0
Latest Information Update: 21 Aug 2023
Price :
$35
*
At a glance
- Drugs Avatrombopag (Primary)
- Indications Thrombocytopenia
- Focus Adverse reactions
- Acronyms APATIT-G
- 14 Aug 2023 Planned End Date changed from 30 Sep 2023 to 30 Sep 2024.
- 14 Aug 2023 Planned primary completion date changed from 30 Sep 2023 to 30 Sep 2024.
- 09 Jun 2022 Status changed from not yet recruiting to recruiting.